Select Publications

Amato RJ et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). Proc ASCO 2007;Abstract 5026.

Escudier B et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. Proc ASCO 2007a;Abstract 3.

Escudier B et al; AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007b;370(9605):2103-11. Abstract

Escudier B et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007c;356(2):125-34. Abstract

Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24. Abstract

Motzer RJ et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006a;24(1):16-24. Abstract

Motzer RJ et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006b;295(21):2516-24. Abstract

Yang JC et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34. Abstract

 

 

 

 

 

 

 

 

Home

Editor
Neil Love, MD

Interviews

Robert J Motzer, MD
- Select publications

Daniel J George, MD
- Select publications

Robert J Amato, DO
- Select publications

Janice P Dutcher, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office